GSK pushes for full RCC approval as Votrient non-inferior to Sutent head-to-head
This article was originally published in Scrip
Executive Summary
A head-to-head study of GlaxoSmithKline's Votrient (pazopanib) and Pfizer's Sutent (sunitinib) in the treatment of advanced or metastatic renal cell carcinoma, the Phase III COMPARZ trial, has demonstrated non-inferiority of GSK's product to Pfizer's.